Porton Pharma Solutions 博腾股份
25 significant filings since 29 May 2026: 14 on equity incentive, 8 on buyback and 1 on pledge released, and 2 other kinds. The latest, on 14 Sep 2026: 关于调整2026年限制性股票激励计划首次授予激励对象名单及权益数量的公告. On 14 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to fall by 876.05% to 1,023.87% from the same period a year earlier.
自 29 May 2026 起有 25 份重大公告:equity incentive 14 份、buyback 8 份、pledge released 1 份,另有 2 类。最新一份(14 Sep 2026):关于调整2026年限制性股票激励计划首次授予激励对象名单及权益数量的公告。14 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期下降 876.05% 至 1,023.87%。
The 80 most recent of 118. 最近 80 条,共 118 条。
Filings are held in full from 1 Jan 2026, broker reports from 2 Jan 2017 and results from 9 Apr 2019. 公告自 1 Jan 2026 起完整收录,研报自 2 Jan 2017 起,业绩自 9 Apr 2019 起。